A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B

References

1. Ayata M., Sugano T., Murayama T., Sakamuro D., Takegami T., Matsumoto Y., Furukawa T. 1994; Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. Journal of Medical Virology 43:386–392
   [Google Scholar]
2. Azuma J., Kurimoto T., Tsuji S., Mochizuki N., Fujinaga S., Matsumoto Y., Masuho Y. 1991; Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. Journal of Immunotherapy 10:278–285
   [Google Scholar]
3. Britt W. J., Vugler L. G. 1992; Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). Journal of Virology 66:6747–6754
   [Google Scholar]
4. Britt W. J., Vugler L., Butfiloski E. J., Stephens E. B. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64:1079–1085
   [Google Scholar]
5. Burton D. R., Williamson R. A., Parren P. W. 2000; Antibody and virus: binding and neutralization. Virology 270:1–3
   [Google Scholar]
6. Burton D. R., Saphire E. O., Parren P. W. 2001; A model for neutralization of viruses based on antibody coating of the virion surface. Current Topics in Microbiology and Immunology 260:109–143
   [Google Scholar]
7. Drew P. D., Moss M. T., Pasieka T. J., Grose C., Harris W. J., Porter A. J. 2001; Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not. Journal of General Virology 82:1959–1963
   [Google Scholar]
8. Fowler K. B., Stagno S., Pass R. F., Britt W. J., Boll T. J., Alford C. A. 1992; The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New England Journal of Medicine 326:663–667
   [Google Scholar]
9. Ho M. 1991; Cytomegalovirus: Biology and Infection . , 2nd edn. pp xix–440 New York: Plenum Medical Book Company;
10. Hopp T. P., Pricket K. S., Price V. L., Libby R. T., March C. J., Cerretti D. P., Urdal D. L., Conlon P. J. 1988; A short polypeptide marker sequence useful for recombinant protein identification and purification. Bio-Technology 6:1204–1210
    [Google Scholar]
11. Kalinke U., Krebber A., Krebber C., Bucher E., Plückthun A., Zinkernagel R. M., Hengartner H. 1996; Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. European Journal of Immunology 26:2801–2806
    [Google Scholar]
12. Loenen W. A., Bruggeman C. A., Wiertz E. J. 2001; Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Seminars in Immunology 13:41–49
    [Google Scholar]
13. Masuho Y., Matsumoto Y., Sugano T., Fujinaga S., Minamishima Y. 1987; Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68:1457–1461
    [Google Scholar]
14. Meyer H., Sundqvist V. A., Pereira L., Mach M. 1992; Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology 73:2375–2383
    [Google Scholar]
15. Navarro D., Lennette E., Tugizov S., Pereira L. 1997; Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. Journal of Medical Virology 52:451–459
    [Google Scholar]
16. Ohizumi Y., Suzuki H., Matsumoto Y., Masuho Y., Numazaki Y. 1992; Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. Journal of General Virology 73:2705–2707
    [Google Scholar]
17. Ohlin M., Sundqvist V. A., Mach M., Wahren B., Borrebaeck C. A. K. 1993; Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. Journal of Virology 67:703–710
    [Google Scholar]
18. Ohlin M., Owman H., Mach M., Borrebaeck C. A. K. 1996; Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Molecular Immunology 33:47–56
    [Google Scholar]
19. Roost H. P., Bachmann M. F., Haag A., Kalinke U., Pliska V., Hengartner H., Zinkernagel R. M. 1995; Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proceedings of the National Academy of Sciences, USA 92:1257–1261
    [Google Scholar]
20. Roy D. M., Grundy J. E. 1992; Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations. Transplantation 54:1109–1110
    [Google Scholar]
21. Schoppel K., Kropff B., Schmidt C., Vornhagen R., Mach M. 1997; The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. Journal of Infectious Diseases 175:533–544
    [Google Scholar]
22. Snydman D. R., Werner B. G., Meissner H. C., Cheeseman S. H., Schwab J., Bednarek F., Kennedy J. L. Jr, Herschel M., Magno A., Levin M. J. and others 1995; Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatric Infectious Disease Journal 14:34–40
    [Google Scholar]
23. Spaete R. R. 1991; A recombinant subunit vaccine approach to HCMV vaccine development. Transplantation Proceedings 23:90–96
    [Google Scholar]
24. Spaete R. R., Gehrz R. C., Landini M. P. 1994; Human cytomegalovirus structural proteins. Journal of General Virology 75:3287–3308
    [Google Scholar]
25. Thorpe R., Bird C. R., Brasher M. D. 1987; Characterisation, standardisation and control of therapeutic immunoglobulin preparations intended for intravenous use. Journal of Infection 15:13–19
    [Google Scholar]
26. Utz U., Britt W., Vugler L., Mach M. 1989; Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 63:1995–2001
    [Google Scholar]
27. Zaia J. A. 1993; Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clinical Infectious Diseases 17 (Suppl. 2):S392–S399
    [Google Scholar]